Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric studies meeting

This article was originally published in The Tan Sheet

Executive Summary

Pediatric subcommittee of FDA's Anti-Infective Drugs Advisory Committee will meet in Bethesda, Md. June 11 to discuss list of drugs that have lost marketing exclusivity but need pediatric studies. Panel also will discuss a template for FDA "written requests" for pediatric studies of proton pump inhibitors in treating gastroesophageal reflux disease. AstraZeneca/P&G's NDA to switch the PPI Prilosec (omeprazole) OTC is focus of a joint Nonprescription Drugs/Gastrointestinal Drugs Advisory Committee meeting June 21 (1"The Tan Sheet" April 29, 2002, p. 3)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS094062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel